Literature DB >> 11576798

Xerostomia in patients with advanced cancer.

A N Davies1, K Broadley, D Beighton.   

Abstract

The aim of the study was to investigate the features of xerostomia in patients with advanced cancer. The protocol involved completion of the Memorial Symptom Assessment Scale, and measurement of the unstimulated whole salivary flow rate (UWSFR) and the stimulated whole salivary flow rate (SWSFR). One hundred twenty patients participated in the study. Xerostomia was the fourth most common symptom (78% of patients). It was associated with a poor performance status (P = 0.01). The usual cause of xerostomia was drug treatment. There was an association with the total number of drugs prescribed (P = 0.009): the median number of xerostomic drugs prescribed was 4. Xerostomia was ranked the third most distressing symptom. Its severity was correlated with the severity of oral discomfort, dysgeusia, dysmasesia, dysphagia, dysphonia, and anorexia. The UWSFR was a relatively sensitive, but nonspecific, investigation. In contrast, the SWSFR was a relatively specific, but insensitive, investigation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11576798     DOI: 10.1016/s0885-3924(01)00318-9

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  8 in total

1.  Long-term tolerability, efficacy and acceptability of fentanyl pectin nasal spray for breakthrough cancer pain.

Authors:  Lukas Radbruch; Luis M Torres; John E Ellershaw; Antonio Gatti; Guillermo Luis Lerzo; Julia Revnic; Donald Taylor
Journal:  Support Care Cancer       Date:  2011-03-22       Impact factor: 3.603

Review 2.  MASCC/ISOO expert opinion on the management of oral problems in patients with advanced cancer.

Authors:  Jac A Jones; Yanin Chavarri-Guerra; Luisa Barreto Costa Corrêa; David R Dean; Joel B Epstein; Eduardo R Fregnani; Jiyeon Lee; Yuhei Matsuda; Valeria Mercadante; Ragnhild Elisabeth Monsen; Natasja J H Rajimakers; Deborah Saunders; Enrique Soto-Perez-de-Celis; Mariana S Sousa; Arghavan Tonkaboni; Arjan Vissink; Keng Soon Yeoh; Andrew N Davies
Journal:  Support Care Cancer       Date:  2022-06-18       Impact factor: 3.603

3.  Oral health conditions affect functional and social activities of terminally ill cancer patients.

Authors:  D J Fischer; J B Epstein; Y Yao; D J Wilkie
Journal:  Support Care Cancer       Date:  2014-03       Impact factor: 3.603

4.  Taste, smell and mouthfeel disturbances in patients with gastrointestinal stromal tumors treated with tyrosine-kinase inhibitors.

Authors:  Jip M van Elst; Nikki S IJzerman; Ron H J Mathijssen; Neeltje Steeghs; Anna K L Reyners; Jacco J de Haan
Journal:  Support Care Cancer       Date:  2021-11-02       Impact factor: 3.603

5.  Palliative care assessment of dry mouth: what matters most to patients with advanced disease?

Authors:  Michelle Fleming; Cheryl L Craigs; Michael I Bennett
Journal:  Support Care Cancer       Date:  2019-06-14       Impact factor: 3.603

6.  Salivary inflammatory mediators as biomarkers for oral mucositis and oral mucosal dryness in cancer patients: A pilot study.

Authors:  Anna Kiyomi; Kensuke Yoshida; Chie Arai; Risa Usuki; Kyosuke Yamazaki; Naoto Hoshino; Akira Kurokawa; Shinobu Imai; Naoto Suzuki; Akira Toyama; Munetoshi Sugiura
Journal:  PLoS One       Date:  2022-04-27       Impact factor: 3.240

Review 7.  Oral symptom assessment tools in patients with advanced cancer: a scoping review.

Authors:  Niamh Cleary; Olivia Munnelly Mulkerrin; Andrew Davies
Journal:  Support Care Cancer       Date:  2022-06-03       Impact factor: 3.359

8.  HPLC-ESI-MS/MS of imidazole alkaloids in Pilocarpus microphyllus.

Authors:  Alexandra C H F Sawaya; Ilka Nacif Abreu; Nathalia Luiza Andreazza; Marcos N Eberlin; Paulo Mazzafera
Journal:  Molecules       Date:  2008-07-30       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.